Block, Inc. Class A (XYZ)
Live price chart, market sentiment, and community perspectives for Block, Inc. Class A (NYSE: XYZ).
Live price chart, market sentiment, and community perspectives for Block, Inc. Class A (NYSE: XYZ).
On our desk, we are seeing strong reactions to the Q2 print where EPS came in at $1.02 against the $0.85 consensus. Management raising full-year 2026 guidance to $4.02 per share is turning heads across institutional accounts. Even with insider selling around $29.8 million recently noted, the underlying gross profit growth of 25% year-over-year makes it hard to ignore the broader fundamental expansion.
When analyzing the ecosystem breakdown, Cash App is clearly carrying the growth narrative with gross profit up 31% to $1.97 billion and lending originations scaling up 59% to $18.9 billion. Meanwhile, Square is lagging behind, showing only 13% gross profit growth and a drop in financial solutions monetization from 0.45% to 0.41%. Analysts need to separate the two segments when building out models.
From a risk management standpoint, the headline numbers look stellar, but the 10-Q filing reveals some serious friction under the hood. Transaction, loan, and consumer receivable losses hit $585.4 million in Q2 alone, pushing the company into a year-to-date net loss of $220.2 million due to legal accruals and higher general and administrative expenses. We are scaling back exposure until credit metrics stabilize.
Watching the sell-side consensus shift after TD Cowen bumped its price target to $105. With 39 research firms maintaining a 'Moderate Buy' rating and a consensus average target sitting near $91.75, the market is pricing in a forward P/E of roughly 19.65. This valuation sits near the upper end of its range for the year, leaving little room for execution missteps.
If you are evaluating management's execution during the Q2 earnings call, the focus on AI-driven development tools, Cash App Borrow, and BNPL expansion deserves close attention. Adjusted operating income reached a record $864 million, representing a 27% margin. The operational leverage is visibly improving, but analysts must weigh whether cost controls can permanently offset rising credit loss provisions.
Explore plasma cleansing, somatic organ swaps, and BCI.